Al makes a very interesting point, and one that raises a
familiar cord.
There is an excellent attorney who specializes in Social
Security Disability cases. He is very selective, pre-
screening his clients for those with legitimate
disabilities, including statin damage and fibromyalgia.
Only half in jest, he related an experience at a lawyers'
confab, where all the other attorneys in the room claimed
to be on the strongest of the statins, as if they thought
that gave them an advantage. He considers the fact that he
is not on Lipitor (but is on one of the older, lower
dosage statins) one of his notable qualifications, in
addition to his excellent record in successfully
representing his clients.
Perhaps some of his colleagues will number among his statin-
disabled clientele soon... not that I wish that horrific
adverse effect on anyone.
The public would do well to seriously consider the potential
for episodes of transient global amnesia and short-term
memory loss in selecting an attorney. Read Dr. Graveline's
excellent book, Lipitor, Thief of Memory. It will make you
also think twice about the pilot of your airliner, the taxi
driver, your children's bus driver, etc.
Finally, BTW, there is a study to find out who is more
likely to get the adverse effects, and how long they take
to resolve:
"Reversibility" of changes, if any, at 2 months
postcessation will be determined. If effects (favorable or
unfavorable) are identified, we will seek to ascertain
whether there are baseline variables that predict who will
be most susceptible to these favorable or adverse
noncardiac effects (i.e., effect modification)." ww-ww-Open โ
w.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubme-
d&dopt=Abstract&list_uids=15020036 Control Clin Trials.
2004 Apr;25(2):178-202. The UCSD Statin Study: a randomized
controlled trial assessing the impact of statins on
selected noncardiac outcomes.
Golomb BA, Criqui MH, White HL, Dimsdale JE.
Department of Economics, University of California, San
Diego, CA, USA.
There has been persistent controversy regarding possible
favorable or adverse effects of statins or of cholesterol
reduction on cognition, mood and behavior (including
aggressive or violent behavior), muscle function, and
quality of life. The UCSD Statin Study seeks to ascertain
the beneficial or adverse effects of statin cholesterol-
lowering drugs on a set of noncardiac endpoints, including
cognition, behavior, and serotonin biochemistry. The study
will enroll 1000 subjects (minimum 20% female) of mixed
ethnicity from San Diego. Subjects must be age 20 and older,
postmenopausal if female, without known cardiovascular
disease or diabetes, and with LDL-cholesterol between 115
and 190 mg/dl. Subjects will be randomized to a double-
blind, placebo-controlled trial with assignment 1/3,
1/3, 1/3 to placebo, simvastatin 20 mg, or pravastatin 40 mg
(equipotent LDL-cholesterol-lowering doses for drug arms
with simvastatin and pravastatin chosen to represent the
extremes of the lipophilicity spectrum) for 6 months of
treatment followed by 2 months postcessation follow-up.
Primary outcomes are cognition (cognitive battery),
irritability/aggression (behavior measure), and serotonin
(gauged by whole blood serotonin), assessed as the
difference between baseline and 6 months, judging combined
statin groups vs. placebo. Secondary outcomes include mood
(CES-D and Wakefield depression inventory), quality of
life (SF-12V), sleep (Leeds sleep scale, modified), and
secondary aggression measures (Conflict Tactics Scale;
Overt Aggression Scale, Modified). Cardiovascular
reactivity will be examined in a 10% subset. As additional
secondary endpoints, primary and selected secondary
outcomes will be assessed by statin assignment (lipophilic
simvastatin vs. hydrophilic pravastatin). "Reversibility"
of changes, if any, at 2 months postcessation will be
determined. If effects (favorable or unfavorable) are
identified, we will seek to ascertain whether there are
baseline variables that predict who will be most
susceptible to these favorable or adverse noncardiac
effects (i.e., effect modification).
PMID: 15020036 [PubMed - in process]
"Al. Lohse" <[email hidden]> wrote in message
"]news:[email hidden]...
Quoted message said:"Statins may also cause cognitive problems."
<snip>
Quoted message said:Quoted message said:I am a lawyer, but don't practice privately. And I am
not anonymous.
Because, "Statins may also cause cognitive problems." you
are on the side of taking advice (a caution) from an
Anonymous Internet Dude, an AID. Doubt Perry Mason (MHRIP)
would ever take an AID seriously.
Always thought lawyers had superior linguistic analytical
abilities. You, apparently, no longer possess such
abilities. Wonder why.
I'll not spell it out. Life is a balancing act. The
English might say, what is gained on the swings is lost on
the round-about.
Best of luck with your heart health, Steve Marcus. We ARE
all in this together.
Regards,
A.L.